{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Faiena I"],"funding":["Kite Pharma Inc."],"pagination":["743-751"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11028196"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["68(5)"],"pubmed_abstract":["<h4>Background</h4>Melanoma-associated antigen-A (MAGE-A) and programmed-death ligand 1 (PD-L1) are present in urothelial carcinoma (UC). We assessed survival outcomes in patients with MAGE-A and PD-L1 expression.<h4>Methods</h4>MAGE-A and PD-L1 expression on neoplastic cells was analyzed using tissue microarrays from patients with UC. We compared differential expression between disease stage and grade. MAGE-A and PD-L1 co-expression was subcategorized. Fisher's exact test was done for categorical variables followed by univariable and multivariable analysis of recurrence-free survival (RFS) and progression-free survival (PFS).<h4>Results</h4>Co-expression of MAGE+/PD-L1+ was higher in advanced disease; however, only MAGE+/PD-L1- was associated with shorter RFS [hazard ratio (HR) 1.89; 95% "],"journal":["Cancer immunology, immunotherapy : CII"],"pubmed_title":["Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma."],"pmcid":["PMC11028196"],"funding_grant_id":["SRA-2018-0493"],"pubmed_authors":["Jain R","Pantuck AJ","Chamie K","Drakaki A","Astrow SH","Faiena I","Elashoff DA","Bot A","Belldegrun AS"],"additional_accession":[]},"is_claimable":false,"name":"Melanoma-associated antigen-A and programmed death-ligand 1 expression are associated with advanced urothelial carcinoma.","description":"<h4>Background</h4>Melanoma-associated antigen-A (MAGE-A) and programmed-death ligand 1 (PD-L1) are present in urothelial carcinoma (UC). We assessed survival outcomes in patients with MAGE-A and PD-L1 expression.<h4>Methods</h4>MAGE-A and PD-L1 expression on neoplastic cells was analyzed using tissue microarrays from patients with UC. We compared differential expression between disease stage and grade. MAGE-A and PD-L1 co-expression was subcategorized. Fisher's exact test was done for categorical variables followed by univariable and multivariable analysis of recurrence-free survival (RFS) and progression-free survival (PFS).<h4>Results</h4>Co-expression of MAGE+/PD-L1+ was higher in advanced disease; however, only MAGE+/PD-L1- was associated with shorter RFS [hazard ratio (HR) 1.89; 95% ","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 May","modification":"2026-06-01T09:17:19.924Z","creation":"2026-04-08T11:05:51.955Z"},"accession":"S-EPMC11028196","cross_references":{"pubmed":["30790015"],"doi":["10.1007/s00262-019-02316-w"]}}